Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
FiercePharma2d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
MM&M9d
‘Check before you inject’: Novo bites back at Hims & Hers Super Bowl ad
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
European Shares Notch Ninth Weekly Gain; Novo Nordisk Jumps
European stocks rose for a ninth straight week, boosted by shares of chemicals companies and Novo Nordisk A/S gains. Traders are also looking ahead to German elections on Sunday.
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...